Expertise:
HIPEC
Cytoreductive Surgery
Peritoneal Mesothelioma
Speciality:
Surgical Oncology
Gender:
Female
Language:
English

Get to Know Dr. Salila S. Hashmi

Surgical oncologist Dr. Salila Hashmi treats patients with peritoneal mesothelioma cancer, often utilizing novel hyperthermic intraperitoneal chemotherapy, also known as HIPEC, which has dramatically improved the length of survival for many.

Before joining City of Hope Atlanta in September 2023, Dr. Hashmi launched the University of Alabama’s HIPEC program in 2022. The difference in survival can be significant with the combination treatment. Studies have shown that patients with mesothelioma receiving only standard, systemic chemotherapy have a median survival of just 12-14 months. Those receiving the cytoreductive surgery and HIPEC have a better than 50% chance of living five years or longer.

In addition, Hashmi, who was specially trained in the use of the combination procedure, treats appendiceal, metastatic colorectal, gastric, liver and pancreatic cancers. She also sees patients with chronic pancreatitis and small bowel diseases.

Prior to joining the O’Neal Comprehensive Cancer Center in Birmingham, Hashmi completed a dual fellowship in complex general surgical oncology and hepato-pancreato-biliary surgery at the University of Calgary in Alberta, Canada.

Specialties of Dr. Salila S. Hashmi

  • Cytoreductive surgery
  • HIPEC
  • Peritoneal mesothelioma cancer
  • Colorectal cancer
  • Appendiceal cancer
  • Gastric cancer
  • Bile duct cancer
  • Chronic pancreatitis

Dr. Salila S. Hashmi’s Experience and Medical Education

  • City of Hope Atlanta
  • O’Neal Comprehensive Cancer Center
  • University of Calgary (Fellowship)
  • Emory University School of Medicine (Residency)
  • Aga Khan University, Karachi, Pakistan (M.D.)

Awards and Certifications

  • American Board of Surgery (Surgery critical care)
  • American Board of Surgery (Surgical oncology)

Publications of Dr. Salila S. Hashmi

  • Hashmi, S.S. et al. (2021, August). Unravelling the Complexity Myth for Minimally Invasive Right Hepatectomy: Liver Parenchymal Features and Their Correlation to Objective Outcomes in Major Anatomical Resections. World Journal of Surgery.
  • Butler, J. et al. (2020, July). New approaches to cancer care in a COVID-19 world. The Lancet Oncology.
  • Lovasik, B. et al. (2020, May). Emergency department visits after pancreatoduodenectomy: examining a novel quality metric. HPB (Oxford).
  • Maxwell, D.W. et al. (2020, January). The hidden costs of open hepatectomy: A 10-year, single institution series of right-sided hepatectomies. The American Journal of Surgery.